Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting

Journal of the American Academy of Dermatology

Volumn 71, Issue 4, 2014, Pages 633-641

  Takeshita, Junko ^a,b   Duffin, Kristina Callis ^c   Shin, Daniel B ^a,b   Krueger, Gerald G ^c   Robertson, Andrew D ^d   Troxel, Andrea B ^b   Van Voorhees, Abby S ^a   Gelfand, Joel M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d National Psoriasis Foundation   (United States)

Author keywords

Dermatology Life Quality Index; Patient reported outcome; Physician Global Assessment; Psoriasis; Psoriasis Area and Severity Index; Quality of life

Indexed keywords

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CUTANEOUS PARAMETERS; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG USE; ERYTHEMA; FEMALE; HUMAN; HYPERPIGMENTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHOTOTHERAPY; PHYSICIAN GLOBAL ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; SELF REPORT; SKIN CLEARANCE; SKIN COLOR; SKIN DISEASE ASSESSMENT; SYSTEMIC THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE; AGE; AGED; COMPARATIVE STUDY; METHODOLOGY; PATHOLOGY; PATIENT SATISFACTION; PATIENT-REPORTED OUTCOME; PSORIASIS; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

DERMATOLOGICAL AGENT;

DERMATOLOGY LIFE QUALITY INDEX; PATIENT-REPORTED OUTCOME; PHYSICIAN GLOBAL ASSESSMENT; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE;

ADULT; AGE FACTORS; AGED; CROSS-SECTIONAL STUDIES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHOTOTHERAPY; PSORIASIS; QUALITY OF LIFE; RISK ASSESSMENT; SELF REPORT; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME; UNITED STATES;

EID: 84910135687     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.05.001     Document Type: Article

References (33)

1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014;70:512-6.
2. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013;149:1173-9.
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
4. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013;149:1180-5.
5. Canadian Psoriasis Guidelines Committee. Canadian Guidelines for the Management of Plaque Psoriasis. June 2009. Available from: URL:http://www. dermatology. ca/wp-content/uploads/ 2012/01/cdnpsoriasisguidelines. pdf. Accessed January 16, 2014.
6. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3 guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl):1-70.
7. Mrowietz U, Kragballe K, Reich K, Spuls P,Griffiths CE,NastA, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011;303:1-10.
8. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Finlay AY, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019.
9. Baker C, Mack A, Cooper A, Fischer G, Shumack S, Sidhu S, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol 2013;54:148-54.
10. Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatization to disability in patients with psoriasis. J Psychosom Res 2001;50:11-5.
11. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav 2000;70:567-71.
12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)ea simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
13. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 1998;23:391-8.
14. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-66.
15. Torii H, Sato N, Yoshinari T, Nakagawa H. Japanese Infliximab Study I. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol 2012;39:253-9.
16. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008;216: 260-70.
17. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012;66:369-75.
18. van Cranenburgh OD, de Korte J, Sprangers MA, de Rie MA, Smets EM. Satisfaction with treatment among patients with psoriasis: a Web-based survey study. Br J Dermatol 2013;169: 398-405.
19. Schaarschmidt ML, Umar N, Schmieder A, Terris DD, Goebeler M, Goerdt S, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol 2013;27:187-98.
20. Callis Duffin K, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol 2014;170:672-80.
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
22. Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol 2012;148:487-94.
23. Food and Drug Administration. Centocor: briefing document for ustekinumab (CNTO 1275). June 17, 2008. Available from: URL:http://www. fda. gov/ohrms/dockets/ac/08/briefing/2008- 4361b1-02-CENTOCOR. pdf. Accessed January 16, 2014.
24. Food and Drug Administration. Enbrel (etanercept) for the treatment of pediatric plaque psoriasis. June 18, 2008. Available from: URL:http://www. fda. gov/ohrms/dockets/ac/08/ briefing/2008-4361b2-01-FDA. pdf. Accessed January 16, 2014.
25. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient-reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003;1:53.
26. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006;4:71.
27. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005;125:659-64.
28. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-6.
29. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med 2008;3:17.
30. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York (NY): John Wiley and Sons; 2000.
31. Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012;26(Suppl):61-7.
32. Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat 2013;24:64-9.
33. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005;19(Suppl):2-6.